Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need.

17 Nov 2009

Antidepressant drug is effective in treating women with low libido

The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found.

17 Nov 2009

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009.

16 Nov 2009

Study finds striking similarities in people with schizophrenia across 37 different countries

An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.

16 Nov 2009

Results from the study on occupational exposure to bisphenol A published

This study of occupational exposure to bisphenol A (BPA) among male factory workers in China provides interesting new information, although its relevance to average consumers who use products containing minute amounts of BPA is limited, at best.

11 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

First human study to measure effects of BPA on male reproductive system

High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals.

11 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

Third-quarter financial results for the year 2009 announced by Biovail

Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain.

5 Nov 2009

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

4 Nov 2009

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference.

29 Oct 2009

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Rexahn Pharmaceuticals, Inc. announced today that it has completed its previously announced Registered Direct Offering of common stock and warrants. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for this transaction.

26 Oct 2009

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Adam Kluger Public Relations (www.adamklugerpr.com) announced today that Dr. Dennis Lin, MD (www.drdennismd.com) has retained the New York based boutique PR firm to provide media support and to promote his psychiatric practice which specializes in sexology, sexual relationships, interpersonal difficulties and couples therapy.

26 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Sexual dysfunction in cancer survivors rarely addressed by internists

Few internists who care for cancer survivors address issues of sexual dysfunction with their patients, according to a study led by Massachusetts General Hospital (MGH) researchers. In their article appearing in a November 2009 cancer survivor supplement to the Journal of General Internal Medicine, now available online, the investigators report that more than half the internists responding to a survey indicated they rarely or never discussed sexual problems with their patients who had survived cancer.

22 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Studies show that physiotherapy can help relieve symptoms of prostatitis

Prostatitis is no picnic. It is a urological condition which causes infection or inflammation of the prostate gland. It is a fairly common health concern, especially for men under 50 and can seriously affect quality of life including sexuality and intimate relationships. However, new research regarding the benefits of physiotherapy in treating prostititis is promising.

14 Oct 2009

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

Antidepressant drug is effective in treating women with low libido

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

Study finds striking similarities in people with schizophrenia across 37 different countries

Results from the study on occupational exposure to bisphenol A published

Potential benefits of Labopharm's novel trazodone formulation published

First human study to measure effects of BPA on male reproductive system

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Third-quarter financial results for the year 2009 announced by Biovail

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Rexahn Pharmaceuticals completes Registered Direct Offering of common stock and warrants

Dr. Dennis Lin retains Adam Kluger Public Relations to promote his psychiatric practice

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Sexual dysfunction in cancer survivors rarely addressed by internists

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

Studies show that physiotherapy can help relieve symptoms of prostatitis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in